Notably, Pvr inhibition by overexpressing a dominant negative form (PvrDN) via He-Gal4 significantly attenuated tumor growth and reduced hemocyte recruitment to QRasV12//M6−/− tumors (Figs. 7I and EV8A,B). The gene discussed is LGALS4; the disease is neoplasm.